Emmanuel Krakaris - Augmedix CEO and President
| AUGXDelisted Stock | USD 2.35 0.00 0.00% |
Insider
Emmanuel Krakaris is CEO and President of Augmedix
| Age | 65 |
| Phone | 888 669 4885 |
| Web | https://www.augmedix.com |
Emmanuel Krakaris Latest Insider Activity
Tracking and analyzing the buying and selling activities of Emmanuel Krakaris against Augmedix stock is an integral part of due diligence when investing in Augmedix. Emmanuel Krakaris insider activity provides valuable insight into whether Augmedix is net buyers or sellers over its current business cycle. Note, Augmedix insiders must abide by specific rules, including filing SEC forms every time they buy or sell Augmedix'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Emmanuel Krakaris over three months ago Disposition of 3525 shares by Emmanuel Krakaris of Augmedix at 2.27 subject to Rule 16b-3 | ||
Emmanuel Krakaris over six months ago Acquisition by Emmanuel Krakaris of 150000 shares of Augmedix subject to Rule 16b-3 |
Augmedix Management Efficiency
The company has return on total asset (ROA) of (0.3061) % which means that it has lost $0.3061 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.2978) %, meaning that it created substantial loss on money invested by shareholders. Augmedix's management efficiency ratios could be used to measure how well Augmedix manages its routine affairs as well as how well it operates its assets and liabilities.Augmedix currently holds 25.85 M in liabilities with Debt to Equity (D/E) ratio of 1.54, which is about average as compared to similar companies. Augmedix has a current ratio of 2.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Augmedix's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Kenneth LaMontagne | In8bio Inc | N/A | |
| William Ho | In8bio Inc | 45 | |
| David Hale | Dermata Therapeutics | 75 | |
| David Dornan | Elevation Oncology | 46 | |
| Lawrence Lamb | In8bio Inc | 69 | |
| John Lorbiecki | Aclarion | 61 | |
| Kate Rochlin | In8bio Inc | 42 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| Valerie MD | Elevation Oncology | 46 | |
| RPh PharmD | Elevation Oncology | 40 | |
| Joseph Ferra | Elevation Oncology | 49 | |
| TaiWei Ho | In8bio Inc | 47 | |
| Trishna MD | In8bio Inc | 45 | |
| Gerald Proehl | Dermata Therapeutics | 65 | |
| Ryan Bond | Aclarion | 52 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
Management Performance
| Return On Equity | -3.3 | |||
| Return On Asset | -0.31 |
Augmedix Leadership Team
Elected by the shareholders, the Augmedix's board of directors comprises two types of representatives: Augmedix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Augmedix. The board's role is to monitor Augmedix's management team and ensure that shareholders' interests are well served. Augmedix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Augmedix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Emmanuel Krakaris, CEO and President | ||
| Saurav Chatterjee, Chief Officer | ||
| Todd Holvick, Head Compliance | ||
| Jonathan Hawkins, Chief Officer | ||
| Tomer Levy, Senior Engineering | ||
| Lia Wallick, Head People | ||
| Davin MD, Chief Officer | ||
| Ian Shakil, Chief Founder | ||
| Paul Ginocchio, Chief Officer | ||
| Sandra Breber, Chief Officer |
Augmedix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Augmedix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.3 | |||
| Return On Asset | -0.31 | |||
| Profit Margin | (0.46) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | 113.21 M | |||
| Shares Outstanding | 49.43 M | |||
| Shares Owned By Insiders | 1.50 % | |||
| Shares Owned By Institutions | 84.78 % | |||
| Number Of Shares Shorted | 1.07 M | |||
| Price To Book | 11.09 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Augmedix Stock
If you are still planning to invest in Augmedix check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Augmedix's history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |